Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
about
Update on rational targeted therapy in AMLNovel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Established and emerging targeted therapies in the myelodysplastic syndromes.Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies.Combination therapy in combating cancer.Clinical significance of DAPK promoter hypermethylation in lung cancer: a meta-analysis.DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acuEpigenetic synergy between decitabine and platinum derivativesSelective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.Paclitaxel plus valproic acid versus paclitaxel alone as second- or third-line therapy for advanced gastric cancer: a randomized Phase II trialA randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN.Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.Transcriptional Selectivity of Epigenetic Therapy in Cancer.The cancer epigenome: Concepts, challenges, and therapeutic opportunities.Emerging biological therapies for the treatment of myelodysplastic syndromes.Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type II.Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia.DNA Hypomethylating Drugs in Cancer Therapy.Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis.Hand-foot syndrome following decitabine.Functional interdependence of BRD4 and DOT1L in MLL leukemia.Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents.Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy.Valproic acid may exerts its cytotoxic effect through rassf1a expression induction in acute myeloid leukemia.A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse.Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS).Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer.Precision therapy for acute myeloid leukemia.Influence of acylpeptide hydrolase polymorphisms on valproic acid level in Chinese epilepsy patients.A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.A comparison of therapeutic dosages of decitabine in treating myelodysplastic syndrome: a meta-analysis.Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia.
P2860
Q26766152-182FCC24-3DD9-4E01-A732-B930E252168CQ26770391-A2AAD977-3BB9-44B4-A871-9E6B1A4A35DAQ30245476-827BD246-9623-42A2-AD45-535369A51455Q33437309-6EDE3500-407E-4EFC-86BB-E14F785EF752Q33762936-2A640FAD-D385-4757-B618-F86F9F1468BDQ33914234-1E75EF44-FA27-4C20-9069-6D9FD333CCB2Q35229048-CB266B74-4669-4252-B0E1-57F8F7549A8BQ35640809-852C9EE8-E87E-410E-AF1D-D7A7371C508EQ36053915-4E84032B-042F-4502-844F-0F1C24082D5DQ36242646-7821760F-0BE5-4749-B1C2-4B4EEF17AE9FQ37138570-BEC355E6-2D63-4187-9949-B29660CE59BFQ38372745-729E55D3-6A5C-4E99-B1E5-535C58C01B01Q38537883-D980D1C4-46FF-4E63-9A48-596BC09FCAD3Q38570399-701EB7B2-EE77-45E1-931E-FA6D22E98704Q38687894-58339709-54C2-46D5-AB85-C4544FB4DDADQ38710509-A41441A2-19A8-41C5-85AC-8A5DE0206639Q38729313-A39D4964-3390-4B8C-AF2F-3A4FB9D9B0B0Q38743881-90B0CC02-32D2-4290-A6C4-60E0776BA62CQ38834981-25AD2334-3C6F-4E58-A594-99A12622D5C0Q38849324-17BE59DF-4BCC-4260-84E3-C2DF2B0AB45CQ38961023-A1459A00-ADF0-4CF9-8F99-280335BAB530Q38967853-4FAB6A12-25DC-420A-8F55-14E933312402Q38979940-06A2D276-354B-4000-9D94-96AE6FD91E6AQ39295844-7D298E23-8CC1-44CB-9370-4A6D00030CBBQ39615789-84280B63-7DA7-4B6D-8596-11C109765433Q39688289-49CBC1D7-EFCE-4D3A-9673-63BEFF7BC565Q40377702-EC653B95-3044-49E6-8AA8-351725A29A3CQ40385613-4075D5E0-40AE-488B-985A-16ED30A7678FQ41612823-1CC0674D-BE89-4E36-B7D0-30C14C28FE33Q41915700-5438F6E9-79C6-477E-AD48-3137C588F321Q47099325-E358D41D-E9B6-4D06-9223-B0D02F389AD0Q47125142-9DE63CC2-84A8-4002-88ED-14696562911EQ47559681-859D67A0-809A-4055-ABDF-63D735BF3607Q48198254-5A621217-84E4-4090-8B49-9D8D0599569CQ48551091-C1F88B15-78F6-4910-BCB9-82436FD0B84EQ49534332-D5907207-81A1-486A-9C0F-B5CEF6FCED04Q51645804-A14080FD-CF71-4571-8842-7FD949CFEC3DQ52641884-2431A0E8-0267-4DA7-85FF-C97A2D900524Q54363269-A7C4B2F7-7E3F-4BBA-B231-015D45CFAFC1Q55433291-9FAA8174-F150-4393-A809-E009B8DAC7E7
P2860
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Results of phase 2 randomized ...... nd acute myelogenous leukemia.
@ast
Results of phase 2 randomized ...... nd acute myelogenous leukemia.
@en
type
label
Results of phase 2 randomized ...... nd acute myelogenous leukemia.
@ast
Results of phase 2 randomized ...... nd acute myelogenous leukemia.
@en
prefLabel
Results of phase 2 randomized ...... nd acute myelogenous leukemia.
@ast
Results of phase 2 randomized ...... nd acute myelogenous leukemia.
@en
P2093
P2860
P50
P356
P1433
P1476
Results of phase 2 randomized ...... nd acute myelogenous leukemia.
@en
P2093
Jean-Pierre Issa
Mark Brandt
Xuelin Huang
P2860
P304
P356
10.1002/CNCR.29085
P407
P50
P577
2014-10-21T00:00:00Z